Literature DB >> 22945471

A novel link between Campylobacter jejuni bacteriophage defence, virulence and Guillain-Barré syndrome.

R Louwen1, D Horst-Kreft, A G de Boer, L van der Graaf, G de Knegt, M Hamersma, A P Heikema, A R Timms, B C Jacobs, J A Wagenaar, H P Endtz, J van der Oost, J M Wells, E E S Nieuwenhuis, A H M van Vliet, P T J Willemsen, P van Baarlen, A van Belkum.   

Abstract

Guillain-Barré syndrome (GBS) is a post-infectious disease in which the human peripheral nervous system is affected after infection by specific pathogenic bacteria, including Campylobacter jejuni. GBS is suggested to be provoked by molecular mimicry between sialylated lipooligosaccharide (LOS) structures on the cell envelope of these bacteria and ganglioside epitopes on the human peripheral nerves, resulting in autoimmune-driven nerve destruction. Earlier, the C. jejuni sialyltransferase (Cst-II) was found to be linked to GBS and demonstrated to be involved in the biosynthesis of the ganglioside-like LOS structures. Apart from a role in pathogenicity, we report here that Cst-II-generated ganglioside-like LOS structures confer efficient bacteriophage resistance in C. jejuni. By bioinformatic analysis, it is revealed that the presence of sialyltransferases in C. jejuni and other potential GBS-related pathogens correlated significantly with the apparent degeneration of an alternative anti-virus system: type II Clusters of Regularly Interspaced Short Palindromic Repeat and associated genes (CRISPR-Cas). Molecular analysis of the C. jejuni CRISPR-Cas system confirmed the bioinformatic investigation. CRISPR degeneration and mutations in the cas genes cas2, cas1 and csn1 were found to correlate with Cst-II sialyltransferase presence (p < 0.0001). Remarkably, type II CRISPR-Cas systems are mainly found in mammalian pathogens. To study the potential involvement of this system in pathogenicity, we inactivated the type II CRISPR-Cas marker gene csn1, which effectively reduced virulence in primarily cst-II-positive C. jejuni isolates. Our findings indicate a novel link between viral defence, virulence and GBS in a pathogenic bacterium.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22945471     DOI: 10.1007/s10096-012-1733-4

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  72 in total

1.  PmST2: a novel Pasteurella multocida glycolipid α2-3-sialyltransferase.

Authors:  Vireak Thon; Kam Lau; Hai Yu; Bao K Tran; Xi Chen
Journal:  Glycobiology       Date:  2011-04-21       Impact factor: 4.313

Review 2.  Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis.

Authors:  David S Stephens
Journal:  Vaccine       Date:  2009-05-23       Impact factor: 3.641

3.  DMS3-42: the secret to CRISPR-dependent biofilm inhibition in Pseudomonas aeruginosa.

Authors:  Kelli L Palmer; Marvin Whiteley
Journal:  J Bacteriol       Date:  2011-05-06       Impact factor: 3.490

4.  Lipooligosaccharide and polysaccharide capsule: virulence factors of Neisseria meningitidis that determine meningococcal interaction with human dendritic cells.

Authors:  Alexandra Unkmeir; Ulrike Kämmerer; Anne Stade; Claudia Hübner; Sabine Haller; Annette Kolb-Mäurer; Matthias Frosch; Guido Dietrich
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

5.  Longitudinal study of Campylobacter jejuni bacteriophages and their hosts from broiler chickens.

Authors:  P L Connerton; C M Loc Carrillo; C Swift; E Dillon; A Scott; C E D Rees; C E R Dodd; J Frost; I F Connerton
Journal:  Appl Environ Microbiol       Date:  2004-07       Impact factor: 4.792

6.  Gangliosides as binding sites in SA-11 rotavirus infection of LLC-MK2 cells.

Authors:  F Superti; G Donelli
Journal:  J Gen Virol       Date:  1991-10       Impact factor: 3.891

7.  Preceding infections and anti-ganglioside antibodies in patients with Guillain-Barré syndrome: a single centre prospective case-control study.

Authors:  S Sinha; K N Prasad; D Jain; C M Pandey; S Jha; S Pradhan
Journal:  Clin Microbiol Infect       Date:  2007-03       Impact factor: 8.067

Review 8.  Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome.

Authors:  Pieter A van Doorn; Liselotte Ruts; Bart C Jacobs
Journal:  Lancet Neurol       Date:  2008-10       Impact factor: 44.182

9.  Evidence for acquisition of the lipooligosaccharide biosynthesis locus in Campylobacter jejuni GB11, a strain isolated from a patient with Guillain-Barré syndrome, by horizontal exchange.

Authors:  Michel Gilbert; Peggy C R Godschalk; Marie-France Karwaski; C Wim Ang; Alex van Belkum; Jianjun Li; Warren W Wakarchuk; Hubert P Endtz
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

10.  CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III.

Authors:  Elitza Deltcheva; Krzysztof Chylinski; Cynthia M Sharma; Karine Gonzales; Yanjie Chao; Zaid A Pirzada; Maria R Eckert; Jörg Vogel; Emmanuelle Charpentier
Journal:  Nature       Date:  2011-03-31       Impact factor: 49.962

View more
  72 in total

1.  Association of clustered regularly interspaced short palindromic repeat (CRISPR) elements with specific serotypes and virulence potential of shiga toxin-producing Escherichia coli.

Authors:  Magaly Toro; Guojie Cao; Wenting Ju; Marc Allard; Rodolphe Barrangou; Shaohua Zhao; Eric Brown; Jianghong Meng
Journal:  Appl Environ Microbiol       Date:  2013-12-13       Impact factor: 4.792

2.  A CRISPR-Cas system enhances envelope integrity mediating antibiotic resistance and inflammasome evasion.

Authors:  Timothy R Sampson; Brooke A Napier; Max R Schroeder; Rogier Louwen; Jinshi Zhao; Chui-Yoke Chin; Hannah K Ratner; Anna C Llewellyn; Crystal L Jones; Hamed Laroui; Didier Merlin; Pei Zhou; Hubert P Endtz; David S Weiss
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-14       Impact factor: 11.205

3.  Nuclease activity of Legionella pneumophila Cas2 promotes intracellular infection of amoebal host cells.

Authors:  Felizza F Gunderson; Celeste A Mallama; Stephanie G Fairbairn; Nicholas P Cianciotto
Journal:  Infect Immun       Date:  2014-12-29       Impact factor: 3.441

Review 4.  The CRISPR-Cas9 system in Neisseria spp.

Authors:  Yan Zhang
Journal:  Pathog Dis       Date:  2017-06-01       Impact factor: 3.166

Review 5.  Suppressing the CRISPR/Cas adaptive immune system in bacterial infections.

Authors:  P Gholizadeh; M Aghazadeh; M Asgharzadeh; H S Kafil
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-06-11       Impact factor: 3.267

Review 6.  A decade of discovery: CRISPR functions and applications.

Authors:  Rodolphe Barrangou; Philippe Horvath
Journal:  Nat Microbiol       Date:  2017-06-05       Impact factor: 17.745

7.  Type I CRISPR-Cas targets endogenous genes and regulates virulence to evade mammalian host immunity.

Authors:  Rongpeng Li; Lizhu Fang; Shirui Tan; Min Yu; Xuefeng Li; Sisi He; Yuquan Wei; Guoping Li; Jianxin Jiang; Min Wu
Journal:  Cell Res       Date:  2016-11-18       Impact factor: 25.617

Review 8.  Phage-Enabled Nanomedicine: From Probes to Therapeutics in Precision Medicine.

Authors:  Kegan S Sunderland; Mingying Yang; Chuanbin Mao
Journal:  Angew Chem Int Ed Engl       Date:  2017-01-24       Impact factor: 15.336

Review 9.  Impact of CRISPR immunity on the emergence and virulence of bacterial pathogens.

Authors:  Asma Hatoum-Aslan; Luciano A Marraffini
Journal:  Curr Opin Microbiol       Date:  2013-12-29       Impact factor: 7.934

10.  Natural Competence and Horizontal Gene Transfer in Campylobacter.

Authors:  Julia Carolin Golz; Kerstin Stingl
Journal:  Curr Top Microbiol Immunol       Date:  2021       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.